30 years ago the first disease-modifying therapy for relapsing multiple sclerosis was approved for use in the United States and soon thereafter across the globe. Since then the field of MS therapeutics, and studies of immunopathogenesis and genetics, have advanced our understanding of the disease and raised the hope of better addressing the next challenges of treating progressive disease, enhancing repair of the damaged nervous system and, hopefully, of a cure. Thirty years into the MS treatment era, the field continues to debate fundamental aspects of MS, and there exists a widening chasm between the triumphs in relapsing disease and the desolation of MS progression, which remains the principal unmet need. In this Personal Viewpoint, we outline lessons learned from the first era of great therapeutic development, as we look to the future of MS research and therapeutics.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology1993; 43(4): 655.
2.
GiovannoniGKnappertzVSteinermanJR, et al. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology2020; 95(8): e1027–e1040.
3.
BergerJR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis2006; 65(Suppl. 3): iii48–iii53.
4.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
5.
KriegerSCAntoineASumowskiJF. EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold. Mult Scler2022; 28(14): 2299–2303.
6.
OkudaDTSivaAKantarciO, et al. For the radiologically isolated syndrome consortium (RISC). Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS ONE2014; 9(3): e90509.
7.
TremlettHMarrieRA. The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. Mult Scler2021; 27(1): 6–12.
8.
TitusHEChenYPodojilJR, et al. Pre-clinical and clinical implications of ‘inside-out’ vs. ‘outside-in’ paradigms in multiple sclerosis etiopathogenesis. Front Cell Neurosci2020; 14: 599717.
9.
ComiGBar-OrALassmannH, et al. For the expert panel of the 27th annual meeting of the European Charcot Foundation. Role of B cells in multiple sclerosis and related disorders. Ann Neurol2021; 89(1): 13–23.
10.
GiovannoniGPopescuVWuerfelJ, et al. Smouldering multiple sclerosis: The ‘real MS’. Ther Adv Neurol Disord2022; 15: 17562864211066751.
11.
BjornevikKCorteseMHealyBC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science2022; 375(6578): 296–301.
12.
CoetzeeTThompsonAJ. Atlas of MS 2020: Informing global policy change. Mult Scler2020; 26(14): 1807–1808.
13.
KeeganBMKaufmannTJWeinshenkerBG, et al. Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Mult Scler2018; 24(11): 1445–1452.
14.
BischofAPapinuttoNKeshavanA, et al. For the University of California, San Francisco MS-EPIC team. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol2022; 91(2): 268–281.
15.
KriegerS. On cave paintings and shallow waters – The case for advancing spinal cord imaging in multiple sclerosis. JAMA Neurol2022; 79(1): 9–10.
16.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: Results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology1996; 46(4): 907–911.
17.
KuhlmannTMocciaMCoetzeeT, et al. For the International Advisory Committee on clinical trials in multiple sclerosis. Multiple sclerosis progression: Time for a new mechanism-driven framework. Lancet Neurol2023; 22(1): 78–88.
18.
LublinFDHäringDAGanjgahiH, et al. How patients with multiple sclerosis acquire disability. Brain2022; 145(9): 3147–3161.
19.
VollmerTLNairKVWilliamsIM, et al. Multiple sclerosis phenotypes as a continuum: The role of neurologic reserve. Neurol Clin Pract2021; 11(4): 342–351.
20.
KriegerSCCookKDe NinoS, et al. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm2016; 3(5): e279.
21.
SumowskiJFRoccaMALeavittVM, et al. Brain reserve and cognitive reserve in multiple sclerosis: What you’ve got and how you use it. Neurology2013; 80(24): 2186–2193.
22.
PittDLoCHGauthierSA, et al. Toward precision phenotyping of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2022; 9(6): e200025.
23.
HawkinsSAMcDonnellGV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry1999; 67: 148–152.
24.
University of California San Francisco MS-EPIC Team, CreeBACHollenbachJA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol2019; 85(5): 653–666.
